Tempus AI (NASDAQ:TEM) CEO Sells 250,000 Shares of Company Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 250,000 shares of the stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $77.47, for a total value of $19,367,500.00. Following the sale, the chief executive officer owned 100,000 shares in the company, valued at $7,747,000. The trade was a 71.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Performance

NASDAQ:TEM traded up $5.65 during midday trading on Thursday, reaching $82.24. 10,773,536 shares of the company traded hands, compared to its average volume of 6,157,478. The firm has a market capitalization of $14.84 billion, a price-to-earnings ratio of -57.11 and a beta of 3.72. The company has a fifty day moving average price of $58.39 and a 200 day moving average price of $53.43. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. Tempus AI, Inc. has a twelve month low of $40.77 and a twelve month high of $104.32.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The firm had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. During the same period last year, the company earned ($0.22) earnings per share. The firm’s revenue for the quarter was up 21.6% on a year-over-year basis. On average, analysts expect that Tempus AI, Inc. will post -1.38 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on TEM shares. TD Cowen restated a “buy” rating on shares of Tempus AI in a research note on Wednesday, July 15th. Weiss Ratings raised Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, September 11th. Needham & Company LLC restated a “buy” rating and issued a $75.00 target price on shares of Tempus AI in a research report on Friday, July 31st. UBS Group assumed coverage on Tempus AI in a research note on Wednesday, September 9th. They set a “neutral” rating and a $70.00 target price on the stock. Finally, Freedom Capital upgraded Tempus AI to a “hold” rating in a research report on Tuesday, June 30th. Eleven investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $69.63.

Institutional Trading of Tempus AI

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. QRG Capital Management Inc. bought a new position in shares of Tempus AI in the second quarter valued at approximately $240,000. WINTON GROUP Ltd bought a new stake in Tempus AI during the second quarter worth approximately $342,000. Engineers Gate Manager LP acquired a new stake in Tempus AI in the second quarter worth approximately $637,000. Integrated Wealth Concepts LLC acquired a new stake in Tempus AI in the second quarter worth approximately $145,000. Finally, Baird Financial Group Inc. boosted its stake in Tempus AI by 3.4% during the 2nd quarter. Baird Financial Group Inc. now owns 30,434 shares of the company’s stock valued at $1,763,000 after purchasing an additional 994 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.